drugset / Trial / NCT03865836

Expanded Access for ATB200/AT2221 for the Treatment of Pompe Disease

NCT03865836 ↗

Expanded access Available Amicus Therapeutics

Summary

This is an expanded access program (EAP) for eligible participants designed to provide access to ATB200/AT2221.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject AT2221 Unknown — —
Subject Cipaglucosidase alfa Protein / enzyme biologic — —